What are the postremission treatment recommendations for intermediate-risk patients with acute myeloid leukemia (AML)?

Updated: Dec 05, 2018
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Cytogenetics [normal cytogenetics, +8, t(9;11), other nondefined] and molecular abnormalities [normal cytogenetics: t(8;21), inv(16), t(16;16): with c-KIT mutation]:

  • High-dose cytarabine 3 g/m2 IV over 3h every 12h on days 1, 3, and 5 for four cycles, or allogeneic stem cell transplantation

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!